MDC1 and cancer: Since the formation of the ATM-dependent MDC1-RNF8 complex is associated with cancer-cell survival in the presence of cisplatin, we propose that ATM inactivation by an ATM inhibitor, which destabilizes the MDC1-RNF8 interaction, would be a possible therapeutic option to restore cisplatin sensitivity even in BIN1-deficient (i.e., cisplatin-resistant) cancer cells (Figure 4F).